Novartis AG shares, NOVN stock listings on the Stock Exchange

Everything you need to know to stay updated on the financial market. Information, trend and graph in real time on the stock exchange quotations of the major stocks on world stock exchanges.

ISIN code: CH0012005267
Sector: Healthcare technology
Industry: Internet software/services

Le actions of Novartis are listed on the Zurich Stock Exchange under the ticker NOVN and on the US index of the NYSE under the ticker NVS.

View the share's listing history on the Zurich Stock Exchange

Company Description

Novartis International AG is a Swiss multinational company operating in the pharmaceutical sector. It designs, manufactures and markets pharmaceutical products. The company was born in 1996 from the merger of two companies Ciba Geigy e Sandoz.
It is based in Basel. In Italy the headquarters are in Origgio.

It is among the largest companies by turnover in the world (20th position) and second in the pharmaceutical sector behind the Pfizer.

Novartis' businesses are divided into three operating divisions:

• Innovative Medicines: composed of the Novartis Pharmaceuticals Business Units, which includes Novartis Gene Therapies, and Novartis Oncology, they develop innovative medicines in the main therapeutic areas, in the production and marketing of generics and biosimilars.
• Advanced Accelerator Applications: operates in the field of molecular nuclear medicine and specializes in radiopharmaceuticals
• Generics and biosimilars: through the Sandoz division, it markets generics and biosimilar drugs at low cost.

Novartis operates directly and through subsidiaries worldwide. It has more than 110.000 employees, in Italy it has about 2.373.

The largest revenues come from the pharmaceutical products sector with about 80% of the total, followed by the generic drugs department. Geographically, the major revenues come from Europe (37,8%) and the United States (34,3%).

Revenue in 2020 was $49,89 billion (+2,51% over the previous year) with a net profit of $8,07 billion.

The company is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA extension), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and Pharmaceutical Research and Manufacturers of America (PhRMA).

Novartis is listed on the Zurich Stock Exchange on the Swiss Market Index and on the NYSE in New York. Novartis shares are currently trading at around 78 francs. Since 1996 the dividend has been progressively increasing. A dividend of 2022 per share is expected for 3,10, an increase of 3,3%. If the General Meeting approves, the dividend will be paid starting from 10 March 2022.

I major shareholders I'm:

• Novartis AG, 3,91%
• Sandoz Family Foundation, 3,66%
• The Vanguard Group Inc, 2,40%
• UBS Asset Management Switzerland AG, 2,33%
• Norges Bank Investment Management, 2,32%
• Novartis Foundation For Employee Participation, 2,02%
• Wellington Management Co. LLP, 1,77%
• Credit Suisse Asset Management (Schweiz) AG, 1,33%

As of December 31, 2021, shareholders are geographically from:

• Switzerland, 46,17%
• United Kingdom, 24,26%
• United States, 23,56%
• Germany, 1,72%
• Luxembourg, 0,73%
• Belgium, 0,69%
• Japan, 0,45%
• France, 0,34%
• Other countries, 2,08%

Novartis held 33,3% of Roche's shares. In October 2021 Novartis announces the exit from Roche's capital and the sale of its shares. The shares are sold to Roche itself for $20,7 billion.

Economic and financial analysis of the company

Novartis was born in 1996 from the merger of the Swiss companies Ciba-Geigy and Sandoz Laboratories.

In 2000, he sold his agrochemical and genetically modified crop business (Novartis Agribusiness); a new company is created, in collaboration with AstraZeneca (Zeneca Agrochemicals), called Syngenta.

In May 2001 it acquired for 3,1 billion euros from Bz Holding Group 20% of the shares of Roche. Two years later the share will rise to 33%.

In 2003, it organized its generics businesses into a single division, merging some of its subsidiaries into one company, reusing the (previously suppressed) brand name of Sandoz.

In 2005 it acquired the hexal, a leading German generic drug company e Eon Labs, a US generic pharmaceutical company, for a total sum of $8,29 billion.

In 2006 he bought the Chiron Corporation. Chiron was divided into three units: Chiron Vaccines, Chiron Blood Testing and Chiron BioPharmaceuticals. Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals, while the other two units were transformed into a new division called Novartis Vaccines and Diagnostics.

In 2007 Novartis sells the Gerber Products Company, company of food products for children and babies, alla Nestlé for 5,5 billion dollars. Gerber Products was bought in 1994 by Sandoz Laboratories and had been owned by Novartis since its inception.

In 2008 he bought 25% of Alcon Laboratories, eye care company, owned by Nestle.

In 2009, he acquired an 85% stake in the Chinese vaccine company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd..

In 2010, it took over the rest of Alcon's capital from Nestlé for $39,3 billion. Create a new division, Alcon, under which it places its subsidiaries Ciba Vision and Novartis Ophthalmics.

In 2011 he bought the diagnostics company for medical laboratories Genoptix.

In 2012 it acquired the Fougera Pharmaceuticals for $1,5 billion to become the world's largest generic drug maker in the dermatology industry. Fougera will be integrated into the group's Sandoz division.

In February 2014 he bought the CoStim Pharmaceuticals.

In June 2015 he bought the Spinifex Pharmaceuticals for more than 200 million dollars. Sells its Novartis Vaccines and Diagnostics division.

In November 2016, Novartis announces the acquisition of Selexys Pharmaceuticals for 665 million dollars while in December it buys the companies EncoreVision e Ziarco Group Limited.

In October 2017 it acquired the Advanced Accelerator Applications for $3,9 billion. AAA will become a new division of the group.

In March 2018 he reached an agreement with the GlaxoSmithKline for the sale of the 36,5% stake in their joint venture Consumer Healthcare which deals with self-medication products and over-the-counter drugs, for 13 billion dollars.

On April 9, 2019 it was announced spin-off of Alcon as a separate business entity. Alcon is listed on the Swiss stock exchange and on the NYSE in the United States.

In November, it buys the Japanese business of Aspen Global Inc for $330 million to strengthen the company's presence in Asia.
Novartis also announces that it has reached an agreement for buy the American The Medicines Company for $9,7 billion ($85 per share).

During 2020 he buys the company Amblyotech e See Bio for 280 million dollars. At the end of the year he announces the purchase of Cadent Therapeutics for 770 million dollars.

In October 2021 Novartis announces exit from Roche share capital. Roche acquires the entire stake in Novartis (equal to 53,3 million shares) for 20,7 billion euros.

In December 2021 Novartis is shopping in London e buys the British ocular gene therapy company, Gyroscope Therapeutics, for a 1,5 billion dollars.